Abivax SAIn a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.
Tag Archive for: Abivax
The French Abivax SA has had a new CEO since the beginning of May. Marc de Garidel took over the position and became interim chairman of the supervisory board.
France-based Abivax SA announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as its new Chief Medical Officer. He will assume the new role in the beginning of March.